Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1611027 | 1.00 | MMP12 (0.42) | MMP12S1PR1S1PR3CTSLCTSB | |
| SCHEMBL1609669 | 0.83 | TSHR (0.43) | TSHRPPARAPPARD | |
| SCHEMBL8300835 | 0.73 | MMP12 (0.74) | MMP12CTSLCTSBCTSSCTSK | |
| SCHEMBL8298929 | 0.73 | MMP12 (0.74) | MMP12CTSLCTSBCTSSCTSK | |
| SCHEMBL7373878 | 0.70 | MEN1 (0.46) | HDAC6 | |
| SCHEMBL7410121 | 0.70 | MMP2 (0.47) | — | |
| SCHEMBL1610092 | 0.68 | TSHR (0.45) | S1PR3TSHRPPARAPPARDHDAC4 | |
| SCHEMBL3618510 | 0.68 | HDAC6 (0.42) | MMP12S1PR1S1PR3CTSLCTSB | |
| SCHEMBL8197269 | 0.67 | MMP1 (0.42) | MMP12 | |
| SCHEMBL8197822 | 0.67 | MMP1 (0.42) | MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7358265-B2 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (R&D) LTD | 2008-04-15 | — | — | US | claimed |
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2011-04-14 | — | — | US | disclosed |
| US-20100035943-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (OXFORD) LTD (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20080227833-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2008-09-18 | — | — | US | disclosed |
| US-7358265-B2 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (R&D) LTD | 2008-04-15 | — | — | US | disclosed |
| EP-1476438-B1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20050222189-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (OXFORD) LTD (GB) | 2005-10-06 | — | — | US | disclosed |
| WO-2004101537-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2004-11-25 | — | — | WO | disclosed |
| EP-1476438-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | Vernalis (Oxford) Ltd (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003070711-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222189-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | MMP9, TIMP3, MMP13 | MMP12 5/4885S1PR1 3544/4885S1PR3 2981/4885 |
| US-20100035943-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | MMP12, TIMP3, MMP9 | MMP12 1/4885S1PR1 4464/4885S1PR3 4072/4885 |
| US-20080227833-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | MMP12 1/4885S1PR1 4464/4885S1PR3 4072/4885 |
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | MMP12 1/4885S1PR1 4464/4885S1PR3 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.